Open AccessTarin stimulates granulocyte growth in bone marrow cell cultures and minimizes immunosuppression by cyclo-phosphamide in mice
Author(s) -
Lyris Anunciata Demétrio Mérida,
Érika Bertozzi de Aquino Mattos,
Anna Caroliitzsche Teixeira Fernandes Corrêa,
Patrícia M. R. Pereira,
Vânia Margaret Flosi Paschoalin,
Maria F. B. Pinho,
Mauricio Afonso Vericimo
Publication year - 2018
Publication title -
plos one
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.99
H-Index - 332
ISSN - 1932-6203
DOI - 10.1371/journal.pone.0206240
Subject(s) - bone marrow , leukopenia , immunology , progenitor cell , haematopoiesis , cyclophosphamide , biology , immunosuppression , cancer research , stem cell , chemotherapy , microbiology and biotechnology , genetics
Chemotherapeutic drugs, such as cyclophosphamide, cause severe immunosuppression and patients become susceptible to infections. Based on this, the immunomodulatory potential of tarin, a lectin from Colocasia esculenta , was evaluated in bone marrow cell cultures and in cyclophosphamide-immunosuppressed mice. Tarin promoted maintenance of hematopoietic progenitors and repopulation of Gr1 cells in vitro which was supported by in vivo results. In immunosuppressed mice, tarin increased bone marrow cell numbers and altered cell profile distribution by enhancing the frequency of Gr1 + progenitors, including Ly6-C int Ly6-G lo , and anticipating their proliferation/differentiation in mature cells, especially Ly6-C lo Ly6-G hi . Bone marrow cells harvested from tarin-treated immunosuppressed mice proliferated in response to GM-CSF or G-CSF in vitro and, the low numbers of bone marrow cells in the G0 phase, combined with a high number cells undergoing apoptosis confirmed that tarin promoted a faster and intense proliferation/differentiation, even in the presence of CY-induced toxicity. As a result, tarin minimized leukopenia in immunosuppressed mice promoting a faster recovery of peripheral leucocytes and protected erythroid bone marrow cells from CY-cytotoxicity in a dose-dependent manner. Data suggest that tarin could be considered a potential adjuvant to decrease leukopenia and possibly ameliorate anemia, if carefully evaluated in human cancer cell lineages and in clinical trials.